Groundbreaking advances in gene editing technologies continue to push the boundaries of precision medicine. Researchers at UC San Diego and Yale have developed small nuclear RNA base editing as a safer alternative to traditional CRISPR-Cas9 editing, reducing off-target effects and genomic errors. Similarly, MIT scientists engineered prime editors with lower indel mutation rates, enhancing gene therapy safety and efficacy. Additionally, a personalized mRNA-based CRISPR therapy was rapidly developed and dosed in a single-patient compassionate use case, exemplifying the potential for lifesaving customized treatments. These innovations collectively promise improved therapeutic options for genetic and developmental disorders.